Renascience Inc.
Tokyo Stock Exchange 4889.T
Renascience Inc. Price to Sales Ratio (P/S) on January 14, 2025: 33.36
-
Renascience Inc. 52-week high Price to Sales Ratio (P/S) is 33.36 on January 14, 2025, which is 0.00% below the current Price to Sales Ratio (P/S).
-
Renascience Inc. 52-week low Price to Sales Ratio (P/S) is 16.80 on December 26, 2024, which is -49.63% below the current Price to Sales Ratio (P/S).
-
Renascience Inc. average Price to Sales Ratio (P/S) for the last 52 weeks is 21.45.
| Date | Price to Sales Ratio (P/S) | Price to Book Ratio (P/B) | Dividend Yield | Free Cash Flow Yield |
|---|
| CEO | Keisuke Furuta |
| IPO Date | Sept. 24, 2021 |
| Location | Japan |
| Headquarters | 401 Kyodo Building |
| Employees | 4 |
| Sector | Health Care |
| Industries | |
Renascience Inc. engages in the development and commercialization of pharmaceuticals and medical devices in Japan. The company is developing RS5614, a PAI-1 inhibitor product candidate for use in the treatment of chronic myeloid leukemia, malignant melanoma, non-small cell lung cancer, novel coronavirus infections, and FGF23-related hypophosphatemic rickets that is in Phase 3 clinical trials; RS5441, a PAI-1 inhibitor for use in dermatological diseases that is in Phase I clinical trials; and RS8001, a water-soluble vitamin for use in the treatment of premenstrual syndrome/premenstrual dysphoric mood disorder, autism spectrum disorder, and menopausal disorder, which is in Phase 2 clinical trials. It is also developing RS9001, a disposable ultrafine endoscope; artificial intelligence based medical solutions; and diagnostic solutions. The company was incorporated in 2000 and is headquartered in Tokyo, Japan.
Past 5 years
StockViz Staff
January 15, 2025
Any question? Send us an email